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Abstract 
Recently, 2 small molecule kinase inhibitors (TKIs), targeting epidermal growth factor 
receptor (EGFR), have proven effective in the treatment of non-small cell lung cancer. 
However, it is unknown whether the EGFR double activating mutation of L858R in exon 
21 and the in-frame deletion in exon 19 is a predictor of the effectiveness of EGFR-TKIs. 
We report for the first time a case of non-small cell lung cancer with central nervous 
system metastases harboring a rare EGFR double activating mutation who showed a 
good clinical response to erlotinib, regardless of his poor performance status, as 
swallowing is not possible. Therefore, we suggest that erlotinib may become a 
therapeutic choice in cases of central nervous system metastases even with poor 
performance status. 
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Introduction 
Lung cancer is a major cause of cancer-related mortality worldwide and is expected to 
remain a major health problem for the foreseeable future. Chemotherapy is the 
cornerstone of the management of the disease; however, its therapeutic impact on patient 
survival has been modest. Recent discoveries have provided greater understanding of the 
molecular basis of the disease, and the success of 2 small molecule kinase inhibitors 
(TKIs), gefitinib (Iressa, AstraZeneca, London, UK) and erlotinib (Tarceva, OSI 
Pharmaceuticals, Melville City, N.Y., USA), against epidermal growth factor receptor 
(EGFR) in the treatment of non-small cell lung cancer (NSCLC) has provided evidence 
for the effectiveness of the strategy. Erlotinib and gefitinib inhibit the tyrosine kinase 
activity of EGFR and have been studied extensively. Since Lynch et al. have identified 
specific activating mutations within the tyrosine kinase domain of EGFR [1], the missense 
mutation L858R in exon 21 and the in-frame deletion in exon 19, nested around the 
amino acid residues 747 to 750 of the EGFR polypeptide, account for >85% of all clinically 
important mutations related to TKI sensitivity [2]. The detection of EGFR mutations in 
tumor tissues has been applied for predicting the response of TKI treatment and hence 
guiding the treatment for advanced NSCLC. A panel of 30 EGFR kinase domain 
mutations that were recently reported in NSCLC patients was cloned and expressed for 
analysis of kinase activity, transforming potential, and drug sensitivity. These mutations 
affect the N-lobe (exons 18–20) and the C-lobe (exon 21) of the EGFR kinase domain [3], 
however it is uncertain whether the EGFR double activating mutation is a predictor of the 
effectiveness of EGFR-TKIs. 
Patients with central nervous system (CNS) metastases in general suffer from 
deterioration of performance status (PS) and do not have a long survival time. The 
primary treatment for CNS metastases in patients with NSCLC has traditionally consisted 
of whole-brain radiotherapy, surgery, or radiosurgery, while systemic chemotherapy has 
been thought to play a limited role because of the belief that the brain is a pharmacologic 
sanctuary site [4, 5]. Several articles in which CNS metastases were improved by erlotinib 
have been reported [6–11]; however, it remains unknown whether CNS metastases are 
improved by erlotinib in a NSCLC case harboring EGFR double activating mutation with 
a poor PS. 
We report, for the first time, a case of NSCLC with CNS metastases harboring an 
EGFR double activating mutation that showed a good clinical response to erlotinib even 
with a poor PS. 
Case Report 
The patient was a 60-year-old Japanese man with no smoking history and PS 1 (table 1). He suffered 
from prolonged left chest pain on our 1st visit. Evaluation at another facility revealed a nodule in the left 
lung measuring 3.5 cm in diameter, multiple mediastinal contralateral lymph node metastases, multiple 
brain metastases, and left pleural effusion and disseminations. Pathologic examination of specimens 
obtained by transbronchial biopsy from the left lung mass revealed adenocarcinoma (fig. 1) with a 
disease stage of cT4N3M1. To choose a therapeutic strategy, we investigated the EGFR gene mutation 
status of the transbronchial biopsy specimen with the PNA-LNA clamp method [12–14] and detected 
an EGFR gene double activating mutation; L747-S752 deletion in exon 19 and L858R in exon 21. 
Cancer cells were obtained from paraffin-embedded biopsy specimens by manual microdissection. 
The definition of a small specimen is that the quantity of the specimen is sufficient to make a pathologic 
diagnosis; at most several hundred tumor cells are necessary. Formalin-fixed paraffin-embedded tissue 
was cut in 6–8 μm sections, and mounted on pre-treated glass slides. Noncancer cells and necrotic parts 
were manually removed from the slide under the microscope. The slides were deparaffinized, then DNA  
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was extracted with phenol-chloroform and ethanol precipitation. A PNA-LNA PCR clamp, which was 
designed to detect 11 different EGFR mutations, was used for determination of the EGFR gene mutation 
status [12–14]. In this study, we adopted the PNA-LNA PCR clamp for analysis of the EGFR somatic 
mutations. In the PNA-LNA PCR clamp, other types of EGFR mutations are used to control for 
amplification by the clamp primer. In this case, a direct sequencing method was employed to seek other 
types of EGFR mutations. 
On the basis of the results of molecular analysis, the patient received carboplatine (area under the 
concentration-time curve 5) and paclitaxel (180 mg/m
2) intravenously on day 1 of a 3-week cycle. Both 
the pulmonary lesion and the left pleural effusion and disseminations showed stable disease, as assessed 
by response evaluation criteria in solid tumors [15]. After he was on medication for 3 courses with 
stable disease, he developed seizures and multiple brain lesions (fig. 2a, b, c). He then received the oral 
EGFR-TKI erlotinib as the 2nd-line treatment. Upon administration of erlotinib, he could not swallow 
because of disturbance of consciousness so we administered erlotinib dissolved in water from a nasal 
tube. 
He was also administered hydantoin as an anticonvulsant which induced cytochrome CYP3A4 and 
might promote metabolism of erlotinib. Therefore, we performed pharmacokinetic analyses of erlotinib 
and OSI-420 on days 1 and 8 after starting its administration. Blood samples were obtained at 5 points a 
day: just before administration (C0), 2 h (C2), 4 h (C4), 8 h (C8), and 24 h (C24) after administration. 
The concentrations were determined by high-performance liquid chromatography with ultraviolet 
detection, as previously reported [16]. Before analysis, we got written informed consent from the 
patient. Surprisingly, although the serum concentration of erlotinib was quite low (Cmax 925 ng/ml on 
day 8, fig. 3 and table 2), the signs of brain metastases improved dramatically (fig. 2) and his PS 
recovered from 4 to 1. He has remained on erlotinib and has been without evidence of disease 
progression for about 2 months. 
Discussion 
In this case, the Cmax of erlotinib on day 8 was 956 ng/ml, which was remarkably lower 
than the plasma concentration previously reported [17]. The low plasma concentration 
may be due to CYP3A4 induced by hydantoin. In spite of the low plasma concentration, 
the patient showed a good clinical response of his multiple brain metastases and his PS 
recovered dramatically from 4 to 1. 
Erlotinib inhibits the activity of the EGFR tyrosine kinase in intact tumor cells, with 
50% inhibitory concentration values of 20 nmol/l (7.9 ng/ml) [18]. In a study of athymic 
mice with human carcinomas, the plasma concentration of erlotinib associated with a 
50% inhibition of EGFR tyrosine kinase was estimated at 8–12 μmol/l (3.1–4.7 μg/ml) 
[19]. According to these reports, although the plasma concentration was relatively low 
compared to previously reported results [17], 956 ng/ml on day 8 is above the IC50. 
Therefore, this may be the 1st reason for the patient’s good clinical response. 
Erlotinib is metabolized in the liver, mainly by the cytochrome CYP3A4 
(approximately 80%). Erlotinib and its metabolites are excreted predominantly via the 
feces [20]. Although the administration of erlotinib dissolved in water is expected to yield 
a good absorption, the plasma concentration of erlotinib was quite low. In our opinion, 
the reason may be cytochrome CYP3A4. Thus in administration of erlotinib, 
coadministration with medicine that might induce cytochrome CYP3A4 may affect the 
plasma concentration of erlotinib more than we expected. Such a coadministration may 
contribute to a poor clinical response to erlotinib. 
In terms of EGFR-TKI sensitivity, Kancha et al. have identified 4 sets of mutations 
based on their drug sensitivity profiles: (a) mutations that are very sensitive to all 3 drugs 
tested with IC50 values in the low nanomolar range (L858R and Del 747–753insS), (b) 
mutations that are less sensitive to gefitinib (IC50 >100 nmol/l) but sensitive to both 
erlotinib and AEE788 (G719S, V742A, and R776C; IC50 < 100 nmol/l), (c) mutations that  
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are less sensitive to both gefitinib and erlotinib but sensitive to AEE788 (D761N, S768I, 
S784F, L838V, and L861Q), and (d) mutations that are resistant to all three drugs tested 
(N826S and T790M) [3]. To our knowledge, reports concerning cases with an EGFR 
double activating mutation are few. Sriuranpong et al. reported one case with an EGFR 
double activating mutation in Thailand [21]. Zhang et al. described 5 cases with EGFR 
double activating mutation in Chinese patients [22]. In the Zhang report, exon 19 
deletion + L858R double mutations were located on the same allele and the double 
mutant had a higher sensitivity to TKIs than the other two single activating mutation in 
the in vitro study. Although it remains unknown whether the double mutant shows good 
clinical response to erlotinib, this may be the 2nd reason of the patient’s good clinical 
response. To our knowledge, this is the first case with a good clinical response to erlotinib 
harboring this EGFR double activating mutation. 
In addition, several articles in which CNS metastases were improved by erlotinib have 
been reported [6–11] and Katayama et al. reported that erlotinib was a reasonable option 
for the treatment of CNS diseases that appeared after a good initial response of extra CNS 
lesions to gefitinib [9]. However, very little is known about the CNS penetration of and 
exposure to this drug [23–25]. In our case, CNS metastases were improved by erlotinib 
regardless of low plasma concentration, poor PS, and disturbance of consciousness. 
Therefore, in cases with CNS metastases, even if they suffer from deterioration of PS, 
erlotinib may become a therapeutic choice when the cytotoxic agents are not appropriate. 
 
 
 
Table 1. Patient’s background 
EGFR mutation 
exon 19  exon 21 
 Age  Gender  Histology  Smoking  status  PS  Stage  Metastatic
lesion 
L747-S752del 2573T>G:L858R    60  male  adenocarcinoma  never  smoker  1  cTN3M1/IV brain 
 
 
Table 2. The pharmacokinetics parameters and serum concentrations of erlotinib and OSI-420 
Erlotinib OSI-420   
AUC0-24 
ng × h/ml 
Cmax 
ng/ml 
tmax 
h 
t1/2 
h 
 
AUC0–24 
ng × h/ml 
Cmax 
ng/ml 
tmax 
h 
t1/2 
h 
Day 1  14,178  824  8  15.7    1,029  059 8 20.1 
Day 8  16,936  925  2  64.6    1,895  101  4  69.4 
Cmax = Maximal plasma concentration; tmax = time to Cmax; t1/2 = half period. 
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Fig. 1. High-power magnification of a tumor specimen of the left lung nodule shows adenocarcinoma. 
 
 
 
Fig. 2. Brain MRI of the current case. a On our 1st visit. b The signs of CNS metastases were revealed 
before administration of erlotinib. c 4 weeks after initiation of erlotinib, the signs had improved. 
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Fig. 3. Plasma concentration-time plots of erlotinib and OSI-420 in case 1 on days 1 and 8. Arrows 
indicate administration of 150 mg erlotinib. 
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